Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids

Robert S. Weinstein, Jin Ran Chen, Cara C. Powers, Scott A. Stewart, Reid D. Landes, Teresita Bellido, Robert L. Jilka, A. Michael Parfitt, Stavros C. Manolagas

Research output: Contribution to journalArticle

282 Citations (Scopus)

Abstract

Glucocorticoids depress bone formation by inhibiting osteoblastogenesis and increasing osteoblast apoptosis. However, the role of bone resorption in the initial rapid phase of bone loss characteristic of glucocorticoid-induced osteoporosis is unexplained, and the reason for the efficacy of bisphosphonates in this condition remains unknown. We report that in murine osteoclast cultures, glucocorticoids prolonged the baseline survival of osteoclasts and antagonized bisphosphonate-induced caspase activation and apoptosis by a glucocorticoid receptor-mediated action. Consistent with the in vitro evidence, in a murine model of glucocorticoid-induced osteoporosis, the number of cancellous osteoclasts increased, even though osteoclast progenitor number was reduced. Moreover, in mice receiving both glucocorticoids and bisphosphonates, the expected proapoptotic effect of bisphosphonates on osteoclasts was abrogated, as evidenced by maintenance of osteoclast numbers and, additionally, loss of bone density. In contrast, bisphosphonate administration prevented glucocorticoid-induced osteoblast apoptosis. These results indicate that the early loss of bone with glucocorticoid excess is caused by extension of the life span of pre-existing osteoclasts, an effect not preventable by bisphosphonates. Therefore, the early beneficial effects of these agents must be due, in part, to prolonging the life span of osteoblasts.

Original languageEnglish (US)
Pages (from-to)1041-1048
Number of pages8
JournalJournal of Clinical Investigation
Volume109
Issue number8
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Diphosphonates
Osteoclasts
Glucocorticoids
Apoptosis
Osteoblasts
Osteoporosis
Bone and Bones
Glucocorticoid Receptors
Bone Resorption
Caspases
Life Expectancy
Osteogenesis
Bone Density
Maintenance

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. / Weinstein, Robert S.; Chen, Jin Ran; Powers, Cara C.; Stewart, Scott A.; Landes, Reid D.; Bellido, Teresita; Jilka, Robert L.; Michael Parfitt, A.; Manolagas, Stavros C.

In: Journal of Clinical Investigation, Vol. 109, No. 8, 2002, p. 1041-1048.

Research output: Contribution to journalArticle

Weinstein, RS, Chen, JR, Powers, CC, Stewart, SA, Landes, RD, Bellido, T, Jilka, RL, Michael Parfitt, A & Manolagas, SC 2002, 'Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids', Journal of Clinical Investigation, vol. 109, no. 8, pp. 1041-1048. https://doi.org/10.1172/JCI200214538
Weinstein, Robert S. ; Chen, Jin Ran ; Powers, Cara C. ; Stewart, Scott A. ; Landes, Reid D. ; Bellido, Teresita ; Jilka, Robert L. ; Michael Parfitt, A. ; Manolagas, Stavros C. / Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. In: Journal of Clinical Investigation. 2002 ; Vol. 109, No. 8. pp. 1041-1048.
@article{d316840b159744df8d501be875ea7fc4,
title = "Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids",
abstract = "Glucocorticoids depress bone formation by inhibiting osteoblastogenesis and increasing osteoblast apoptosis. However, the role of bone resorption in the initial rapid phase of bone loss characteristic of glucocorticoid-induced osteoporosis is unexplained, and the reason for the efficacy of bisphosphonates in this condition remains unknown. We report that in murine osteoclast cultures, glucocorticoids prolonged the baseline survival of osteoclasts and antagonized bisphosphonate-induced caspase activation and apoptosis by a glucocorticoid receptor-mediated action. Consistent with the in vitro evidence, in a murine model of glucocorticoid-induced osteoporosis, the number of cancellous osteoclasts increased, even though osteoclast progenitor number was reduced. Moreover, in mice receiving both glucocorticoids and bisphosphonates, the expected proapoptotic effect of bisphosphonates on osteoclasts was abrogated, as evidenced by maintenance of osteoclast numbers and, additionally, loss of bone density. In contrast, bisphosphonate administration prevented glucocorticoid-induced osteoblast apoptosis. These results indicate that the early loss of bone with glucocorticoid excess is caused by extension of the life span of pre-existing osteoclasts, an effect not preventable by bisphosphonates. Therefore, the early beneficial effects of these agents must be due, in part, to prolonging the life span of osteoblasts.",
author = "Weinstein, {Robert S.} and Chen, {Jin Ran} and Powers, {Cara C.} and Stewart, {Scott A.} and Landes, {Reid D.} and Teresita Bellido and Jilka, {Robert L.} and {Michael Parfitt}, A. and Manolagas, {Stavros C.}",
year = "2002",
doi = "10.1172/JCI200214538",
language = "English (US)",
volume = "109",
pages = "1041--1048",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "8",

}

TY - JOUR

T1 - Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids

AU - Weinstein, Robert S.

AU - Chen, Jin Ran

AU - Powers, Cara C.

AU - Stewart, Scott A.

AU - Landes, Reid D.

AU - Bellido, Teresita

AU - Jilka, Robert L.

AU - Michael Parfitt, A.

AU - Manolagas, Stavros C.

PY - 2002

Y1 - 2002

N2 - Glucocorticoids depress bone formation by inhibiting osteoblastogenesis and increasing osteoblast apoptosis. However, the role of bone resorption in the initial rapid phase of bone loss characteristic of glucocorticoid-induced osteoporosis is unexplained, and the reason for the efficacy of bisphosphonates in this condition remains unknown. We report that in murine osteoclast cultures, glucocorticoids prolonged the baseline survival of osteoclasts and antagonized bisphosphonate-induced caspase activation and apoptosis by a glucocorticoid receptor-mediated action. Consistent with the in vitro evidence, in a murine model of glucocorticoid-induced osteoporosis, the number of cancellous osteoclasts increased, even though osteoclast progenitor number was reduced. Moreover, in mice receiving both glucocorticoids and bisphosphonates, the expected proapoptotic effect of bisphosphonates on osteoclasts was abrogated, as evidenced by maintenance of osteoclast numbers and, additionally, loss of bone density. In contrast, bisphosphonate administration prevented glucocorticoid-induced osteoblast apoptosis. These results indicate that the early loss of bone with glucocorticoid excess is caused by extension of the life span of pre-existing osteoclasts, an effect not preventable by bisphosphonates. Therefore, the early beneficial effects of these agents must be due, in part, to prolonging the life span of osteoblasts.

AB - Glucocorticoids depress bone formation by inhibiting osteoblastogenesis and increasing osteoblast apoptosis. However, the role of bone resorption in the initial rapid phase of bone loss characteristic of glucocorticoid-induced osteoporosis is unexplained, and the reason for the efficacy of bisphosphonates in this condition remains unknown. We report that in murine osteoclast cultures, glucocorticoids prolonged the baseline survival of osteoclasts and antagonized bisphosphonate-induced caspase activation and apoptosis by a glucocorticoid receptor-mediated action. Consistent with the in vitro evidence, in a murine model of glucocorticoid-induced osteoporosis, the number of cancellous osteoclasts increased, even though osteoclast progenitor number was reduced. Moreover, in mice receiving both glucocorticoids and bisphosphonates, the expected proapoptotic effect of bisphosphonates on osteoclasts was abrogated, as evidenced by maintenance of osteoclast numbers and, additionally, loss of bone density. In contrast, bisphosphonate administration prevented glucocorticoid-induced osteoblast apoptosis. These results indicate that the early loss of bone with glucocorticoid excess is caused by extension of the life span of pre-existing osteoclasts, an effect not preventable by bisphosphonates. Therefore, the early beneficial effects of these agents must be due, in part, to prolonging the life span of osteoblasts.

UR - http://www.scopus.com/inward/record.url?scp=0036123845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036123845&partnerID=8YFLogxK

U2 - 10.1172/JCI200214538

DO - 10.1172/JCI200214538

M3 - Article

C2 - 11956241

AN - SCOPUS:0036123845

VL - 109

SP - 1041

EP - 1048

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 8

ER -